Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

Delayed Quote. Delayed  - 08/29 10:00:00 pm
10.99 USD   -0.72%
08/03 SUCAMPO PHARMAC : reports 2Q loss
08/03 Sucampo Reports Second Quarter 2016 Financial Results
07/29 Paul Edick Joins Sucampo’s Board of Directors
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/23/2016 08/24/2016 08/25/2016 08/26/2016 08/29/2016 Date
11.49(c) 11.09(c) 11.03(c) 11.07(c) 10.99(c) Last
152 193 310 564 342 838 346 747 273 378 Volume
0.00% -3.48% -0.54% +0.36% -0.72% Change
More quotes
Financials ($)
Sales 2016 205 M
EBIT 2016 83,8 M
Net income 2016 27,1 M
Debt 2016 141 M
Yield 2016 -
Sales 2017 226 M
EBIT 2017 108 M
Net income 2017 63,2 M
Debt 2017 89,8 M
Yield 2017 -
P/E ratio 2016 17,44
P/E ratio 2017 7,71
EV / Sales2016 3,15x
EV / Sales2017 2,62x
Capitalization 504 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia.It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
08/26 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
08/08 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
08/03 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
08/03 SUCAMPO PHARMACEUTICALS : reports 2Q loss
08/03 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
08/03 Sucampo Reports Second Quarter 2016 Financial Results
07/29 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regul..
07/29 Paul Edick Joins Sucampo’s Board of Directors
07/20 Sucampo Announces Second Quarter 2016 Earnings Call
07/12 SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
More news
Sector news : Bio Therapeutic Drugs
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
News from SeekingAlpha
08/03 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q2 2016 Results - Earn..
08/03 Sucampo revenues up 49%; Non-GAAP EPS up 10% in Q2
08/03 BIOTECH DAILY DIGEST : A Buyout For Biogen? The Rally Continues. Spotlight On Li..
08/03 Sucampo Pharmaceuticals, Inc. 2016 Q2 - Results - Earnings Call Slides
08/03 Sucampo beats by $0.01, beats on revenue
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 18,5 $
Spread / Average Target 68%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Daniel P. Getman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-36.44%504
AMGEN, INC.5.66%128 351
GILEAD SCIENCES, INC.-22.75%103 158
CELGENE CORPORATION-9.86%83 674
REGENERON PHARMACEUTIC..-26.43%42 053
VERTEX PHARMACEUTICALS..-22.96%24 020
More Results